Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal duration of moxifloxacin therapy in uncomplicated acute cholangitis
2005-004851-37Phase 3Terminated
- Sponsor
- Regensburg University Medical Center
- Start
- Dec 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute cholangitis and cholangiolitis comparing Oral Avalox continuation with Oral placebo continuation (2 arms). Primary endpoint: Combined rate of relapse, complications, and death within 28 days. Started Dec 2007; status: terminated.
02
Drugs
moxifloxacin
03
Conditions
acute cholangitischolangiolitis
Beyond the preview
Go deeper on 2005-004851-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004851-37.